Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)

M. V.Ramana Reddy, Balireddy Akula, Stephen C. Cosenza, Saikrishna Athuluridivakar, Muralidhar R. Mallireddigari, Venkat R. Pallela, Vinay K. Billa, D. R.C.Venkata Subbaiah, E. Vijaya Bharathi, Rodrigo Vasquez-Del Carpio, Amol Padgaonkar, Stacey J. Baker, E. Premkumar Reddy

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl- piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6- carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.

Original languageEnglish (US)
Pages (from-to)578-599
Number of pages22
JournalJournal of Medicinal Chemistry
Volume57
Issue number3
DOIs
StatePublished - Feb 13 2014
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinase 4
Phosphotransferases
Structure-Activity Relationship
Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
pyrido(3,2-d)pyrimidine
AMP-activated protein kinase kinase
Apoptosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). / Reddy, M. V.Ramana; Akula, Balireddy; Cosenza, Stephen C.; Athuluridivakar, Saikrishna; Mallireddigari, Muralidhar R.; Pallela, Venkat R.; Billa, Vinay K.; Subbaiah, D. R.C.Venkata; Bharathi, E. Vijaya; Vasquez-Del Carpio, Rodrigo; Padgaonkar, Amol; Baker, Stacey J.; Reddy, E. Premkumar.

In: Journal of Medicinal Chemistry, Vol. 57, No. 3, 13.02.2014, p. 578-599.

Research output: Contribution to journalArticle

Reddy, MVR, Akula, B, Cosenza, SC, Athuluridivakar, S, Mallireddigari, MR, Pallela, VR, Billa, VK, Subbaiah, DRCV, Bharathi, EV, Vasquez-Del Carpio, R, Padgaonkar, A, Baker, SJ & Reddy, EP 2014, 'Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)', Journal of Medicinal Chemistry, vol. 57, no. 3, pp. 578-599. https://doi.org/10.1021/jm401073p
Reddy, M. V.Ramana ; Akula, Balireddy ; Cosenza, Stephen C. ; Athuluridivakar, Saikrishna ; Mallireddigari, Muralidhar R. ; Pallela, Venkat R. ; Billa, Vinay K. ; Subbaiah, D. R.C.Venkata ; Bharathi, E. Vijaya ; Vasquez-Del Carpio, Rodrigo ; Padgaonkar, Amol ; Baker, Stacey J. ; Reddy, E. Premkumar. / Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 3. pp. 578-599.
@article{c2608695f1b34527820f90cc66809959,
title = "Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)",
abstract = "The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl- piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6- carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.",
author = "Reddy, {M. V.Ramana} and Balireddy Akula and Cosenza, {Stephen C.} and Saikrishna Athuluridivakar and Mallireddigari, {Muralidhar R.} and Pallela, {Venkat R.} and Billa, {Vinay K.} and Subbaiah, {D. R.C.Venkata} and Bharathi, {E. Vijaya} and {Vasquez-Del Carpio}, Rodrigo and Amol Padgaonkar and Baker, {Stacey J.} and Reddy, {E. Premkumar}",
year = "2014",
month = "2",
day = "13",
doi = "10.1021/jm401073p",
language = "English (US)",
volume = "57",
pages = "578--599",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7- oxo-7,8-dihydro-pyrido[2,3- d ]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)

AU - Reddy, M. V.Ramana

AU - Akula, Balireddy

AU - Cosenza, Stephen C.

AU - Athuluridivakar, Saikrishna

AU - Mallireddigari, Muralidhar R.

AU - Pallela, Venkat R.

AU - Billa, Vinay K.

AU - Subbaiah, D. R.C.Venkata

AU - Bharathi, E. Vijaya

AU - Vasquez-Del Carpio, Rodrigo

AU - Padgaonkar, Amol

AU - Baker, Stacey J.

AU - Reddy, E. Premkumar

PY - 2014/2/13

Y1 - 2014/2/13

N2 - The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl- piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6- carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.

AB - The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2-[4-(4-methyl- piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6- carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARK5 kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.

UR - http://www.scopus.com/inward/record.url?scp=84894044278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894044278&partnerID=8YFLogxK

U2 - 10.1021/jm401073p

DO - 10.1021/jm401073p

M3 - Article

C2 - 24417566

AN - SCOPUS:84894044278

VL - 57

SP - 578

EP - 599

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 3

ER -